Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

Benzinga · 1d ago
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.